Focus: Maze Therapeutics is an early-stage biotech focused on small molecules, gene therapy, antisense oligonucleotides, and biologics, headquartered in South San Francisco. The company is in discovery/early clinical phase with minimal revenue-generating activity.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Maze is a high-risk, high-reward pre-revenue biotech best suited for career-stage scientists willing to trade stability for modality expertise and equity participation in an early-stage bet.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Maze Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Maze Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug - Bez Kabli
Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug Bez Kabli
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - Yahoo Finance UK
Maze Therapeutics to Participate in Two Upcoming Investor Conferences Yahoo Finance UK
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information Minichart
Maze Therapeutics Analyst Ratings and Price Targets | NASDAQ:MAZE - Benzinga
Maze Therapeutics Analyst Ratings and Price Targets | NASDAQ:MAZE Benzinga
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts - Yahoo Finance
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts Yahoo Finance
Maze Therapeutics, Inc. (MAZE) reports Q1 loss, beats revenue estimates - MSN
Maze Therapeutics, Inc. (MAZE) reports Q1 loss, beats revenue estimates MSN
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles